MarketCap
Facebook
X
Telegram
Tenax Therapeutics General and Administrative Expenses | TENX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.7 M | 6.78 M | 5 M | 5.68 M | 7.58 M | 5.31 M | 5.08 M | 5.65 M | 5.68 M | 6.25 M | 7.17 M | 13.8 M | 3.68 M | 6.09 M | 7.68 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.7 M | 3.68 M | 7.67 M |
Quarterly General and Administrative Expenses Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.93 M | 5.03 M | 6.48 M | 5.67 M | 5.66 M | - | 1.51 M | 1.34 M | 1.23 M | - | 1.05 M | 1.04 M | 1.27 M | - | 1.38 M | 1.34 M | 1.54 M | - | 2.64 M | 1.27 M | 1.37 M | - | 1.17 M | 869 K | -1.32 M | - | -1.34 M | -1.17 M | -1.18 M | - | -1.19 M | -1.58 M | -1.16 M | - | -1.06 M | -1.79 M | -1.45 M | - | -1.27 M | -1.24 M | 1.76 M | 1.91 M | 1.43 M | 1.23 M | 1.37 M | 1.78 M | 1.59 M | 1.59 M | 1.45 M | 1.44 M | 1.42 M | 1.42 M | 983 K | 1.42 M | 423 K | 423 K | 1.26 M | 2.28 M | 1.66 M | 1.66 M | 1.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.48 M | -1.79 M | 1.2 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
11.5 M | - | - | $ 24.9 M |  USA |
 |
Завод ДИОД
DIOD
|
19.7 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
24.1 M | - | - | - | Russia |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
56 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
13.2 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
37.8 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
11.8 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
82.8 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
28.9 M | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
6.83 M | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
19.8 M | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
124 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
43.8 M | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.83 M | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
18.6 M | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
11.7 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
65.5 M | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
67.1 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
63.6 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
31.7 M | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
1.38 B | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
39.3 M | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
52.9 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
1.75 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
38.4 M | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
20.8 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
49.1 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
49.9 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
4.29 M | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
51.6 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
96.4 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
28.3 M | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Foghorn Therapeutics
FHTX
|
27.6 M | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
93.9 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |
 |
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 9.91 | 0.71 % | $ 271 M | Israel |
 |
Sanofi
SNY
|
9.54 B | $ 41.77 | 0.41 % | $ 51 B | France |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 31.74 | 1.73 % | $ 4.04 B | USA |
 |
Geron Corporation
GERN
|
159 M | $ 1.15 | 2.23 % | $ 767 M | USA |
 |
Gossamer Bio
GOSS
|
37.6 M | $ 9.2 | -4.27 % | $ 2.1 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
4.56 M | - | -3.76 % | $ 3.47 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |